Charles River Laboratories International, Inc.

NYSE:CRL

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

United States

Market Cap

USD 7.24 B

Share Price

USD 147.45

Avg Daily Volume

1,622,587

Change (1 day)

1.49%

Change (1 year)

-29.66%

Change (YTD)

-20.12%

Charles River Laboratories International, Inc. Share Price Year-To-Date (YTD) return on June 20, 2025: -20.12%

Charles River Laboratories International, Inc. Share Price Year-To-Date (YTD) return is -20.12% on June 20, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Charles River Laboratories International, Inc. 52-week low Share Price is USD 245.29 on June 20, 2025, which is 66.35% above the current Share Price.
Charles River Laboratories International, Inc. 52-week low Share Price is USD 99.75 on June 20, 2025, which is -32.35% below the current Share Price.
Charles River Laboratories International, Inc. average Share Price for the last 52 weeks is USD 177.08.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

NYSE: CRL

Charles River Laboratories International, Inc.

CEO	Mr. James C. Foster J.D.
IPO Date	June 23, 2000
Location	United States
Headquarters	251 Ballardvale Street
Employees	18,700
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.